The Phase 1 GALLOP study evaluating the investigational therapy, CB-010, for treatment of lupus nephritis has launched.

Results from randomized controlled trials comparing mycophenolate mofetil versus azathioprine for maintenance therapy in proliferative (class III–IV) lupus nephritis. AZA (120 mg/day ...

Caribou Biosciences has launched a Phase 1 trial testing its CAR T-cell therapy CB-010 for lupus affecting the kidneys and ...

preliminary data in lupus nephritis (LN) patients anticipated in 1H25, data from other patient cohorts expected in 2H25 Patient enrollment in systemic lupus erythematosus (SLE), systemic sclerosis ...

Objectives Lupus nephritis (LN) is a frequent complication of systemic ... Suspected renal relapse involved a kidney biopsy to confirm (class III or class IV LN with active lesions, with or without ...

Objective Randomised trials of type I anti-CD20 antibodies rituximab and ocrelizumab failed to show benefit in proliferative lupus nephritis (LN ... with even greater risk occurring in class IV ...

Lower glucocorticoid dosages were significantly more common with belimumab. Children with lupus nephritis who receive belimumab achieve treatment targets faster, and can taper glucocorticoids ...

Objective Traditional initial treatment regimens for lupus nephritis (LN) used oral glucocorticoids (GC) in starting doses up to 1.0 mg/kg/day prednisone equivalent with or without a preceding ...